Leukemia Program at Northside Hospital

Overview

For adult patients with acute and chronic leukemia, myelodysplastic syndromes, lymphomas, myelomas, and other blood-related malignancies, Northside Hospital's Leukemia Program (NH-Leukemia Program) offers comprehensive, cutting-edge clinical and research-related services.

The recommended course of treatment for some patients with leukemia or other blood cancers may include a blood or bone marrow transplant. We provide a seamless transition to our nationally recognized Blood and Marrow Transplant Program.

A patient with leukemia may need complex care that includes specialized services. Our interdisciplinary team members meet weekly to review and discuss each patient’s treatment plan. Other specialists, including a dedicated health physiologist and social worker, provide psychosocial support to both patients and their caregivers. These healthcare professionals work together to provide a full spectrum of supportive care.

Leukemia Program

NH-Leukemia Program Physicians and Leukemia RN Clinical Coordinators

NH-Leukemia Program FACT’s:

  • Committed to providing comprehensive patient centered care in a compassionate setting.

  • Provides leukemia patients with innovative clinical research trials, outstanding clinical care, and a wide range of services including education, emotional and psychological support.

  • Highly trained, experienced, and dedicated Team

  • Diagnose and treats over 160 new leukemia and hematological malignancy patients each year.

NH-Leukemia Program: Why refer early to NH-BMT?

  • Diagnostic Testing: Extensive diagnostic testing identifies which patients will most likely benefit from a blood or marrow transplant.

    • Follows ASBMT and ASH Guidelines on Recommended Timing for Transplant Consultation, www.ASBMT.org.

  • Early Donor Identification: Family HLA typing initiated early in the treatment phase allows early blood or marrow donor identification.

  • Blood and Marrow Transplant: Seamless integration to the NH-BMT program.

    • Leukemia and BMT coordinators work collaboratively to ensure a smooth transition to the NH BMT program.

    • NH-BMT program is the only adult BMT Program in Georgia to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic transplants for the last 14 consecutive reporting cycles (2009-2022).1,2.

1. For the fourteenth consecutive year (2009-2022), NH-BMT achieved survival outcomes that significantly exceeded the expected range, as reported in the Center for International Blood and Marrow Transplant Research's Final 2022 Transplant Center Specific Survival Report, December 2022, and from reported outcome data from Be The Match®.
2. There were 175 adult and pediatric transplant centers included in the analysis. This survival information includes only patients who received their first allogeneic transplant between January 1, 2018, and December 31, 2020, using unrelated or related donors, and who had reported follow-up. Specific transplant center information can be found at bethematch.org